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Summary 
Clinical trials often judge the efficacy of a new treatment by comparing the survival patterns 
of patients who are randomly assigned to undergo the new or a standard/placebo treatment. 
Usually, the entire groups are analyzed, although certain subgroups of patients may react 
differently to the new treatment than others. Some patients taking the new treatment might 
benefit from it (the positive responders) while others may be harmed by it (the negative 
responders). We applied a newly developed responder identification method (Kehl & Ulm, 
2003) on the doubleblinded placebo controlled European Myocardial Infarction Amiodarone 
Trial (EMIAT). The method, which is based on bump hunting, proceeds to find the so called 
predictive factors, which describe positive and negative trends in survival in special 
subgroups of patients, solely due to Amiodarone. Factors found to be predictive were: age, 
previous infarction, beta-blocker treatment, onset, NYHA classification, and sex. Negative 
responders to Amiodarone, i.e. patients taking Amiodarone who survived shorter than a 
similar group under placebo, were patients who were older than 65 years, have had a previous 
infarction, and were not on beta-blockers. Positive responders to Amiodarone, (longer 
survival time), were male patients who were not negative responders, had NYHA 
classification greater than or equal to two, and onset greater than one. Further studies are 
needed to investigate this hypothesis. 
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Introduction 
In a randomized clinical trial where two treatments are compared, a question of particular 
interest is whether the overall result holds for all patients or if some subgroups respond 
differently to the new treatment. This question is especially important for studies in which the 
new treatment did not show an overall increase in survival compared to placebo (or standard 
treatment) as in the European Myocardial Infarction Amiodarone Trial (EMIAT). Figure 1 
shows the Kaplan-Meier survival curves for the two study arms of EMIAT (Amiodarone & 
placebo) and the log-rank test for difference in survival (p(LR)=.6350). It is possible, 
however, that a certain subgroup of Amiodarone patients have higher or lower survival rates 
than a similar group under placebo. The identification of such subgroups was our aim in this 
analysis. 
Figure 1: Kaplan-Meier survival curve estimates for the placebo and Amiodarone 
treatment arms of EMIAT, p-value of the log-rank statistic for difference in 
survival is 0.6350.  
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The fact that the survival time of a patient taking the new treatment is greater than that of a 
similar patient under placebo can either be due to (i) chance, (ii) better initial prognosis, or 
(iii) the new therapy. Factors responsible for initial prognosis classification are called 
prognostic. Factors describing solely treatment effect are called predictive. Note, that 
predictive factors can be successfully determined only after (all) prognostic factors have been 
adjusted for. We also define positive responders to be patients who benefit from the new 
treatment. Their benefit is expressed in a longer survival time than that of patients with the 
same predictive factors, randomized in the placebo/standard treatment group. We define 
negative responders to be patients who are harmed by the new treatment. Their survival time 
is shorter than that of a similar group of patients under the classical treatment, described by 
some predictive factors. A third group of patients are neither positive nor negative responders. 
Their survival time does not differ from similar patients under placebo.  
Responder identification can be easily done for subgroups defined by one factor. The 
subgroup analysis becomes more complicated when interactions between several factors and 
the treatment define a subgroup. Janse et al (1998), for example, did subgroup analysis of the 
EMIAT data in order to find patients, who may benefit from treatment with Amiodarone – 
they were looking for positive responders. The strategy performed in this substudy of EMIAT 
was to choose four important, readily available baseline characteristics and consider all 
groups resulting from their combinations. Only interactions of up to third order were 
considered. No adjustment for prognostic factors was done. As a result of their analysis, Janse 
et al reported that benefit of prophylactic Amiodarone treatment was seen for patients with 
left-ventricular ejection fraction less than 30%, with arrhythmia on Holter, taking beta-
blockers, and with low baseline heart rate. A slight trend towards benefit was seen for 
patients with ejection fraction between 30% and 40%, without arrhythmia on Holter, off beta-
blockers, and with low baseline heart rate.  
Malik et al (2000) performed subgroup analysis of the EMIAT data set with final aim to test 
the hypothesis that EMIAT patients with depressed heart rate variability (HRV) benefit from 
the Amiodarone treatment (i.e. are positive responders). They performed this analysis by 
developing a Cox-PH model on the entire data set, including treatment and seven prognostic 
factors. The authors fitted models on various subgroups of data and concluded, that patients 
with left-ventricular ejection fraction less than 40% and depressed HRV do benefit from 
prophylactic treatment with Amiodarone. For further details, please refer to the original 
publications. 
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Using the Cox-PH model with treatment interactions for responder identification purposes 
becomes cumbersome very quickly as the level of interaction grows. Our research aimed at 
developing an algorithm which overcomes the hurdle of high power interaction terms. With 
the help of the bump hunting procedure (Friedman & Fisher, 1999), we developed a method 
which is able to identify positive and negative responders in clinical studies. Note, that this is 
a post-hoc analysis, therefore, the resulting models cannot be characterized with a goodness of 
fit criterion. Additional studies are necessary for testing the hypothesis developed in 
responder analysis.  
This paper presents the results of an application of our method on the EMIAT data set, in 
which the new treatment showed no significant overall effect. Due to the large costs, no 
additional studies have been performed up to now. 
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Methods 
Responder identification was performed using the responder identification method described 
in Kehl & Ulm (2003).  
In the first step of the suggested method, a prognostic model (we used a Cox-PH model) is 
developed on the standard treatment group (in the case of EMIAT – on placebo) in order to 
adjust for prognostic factors. The model is then applied on the new treatment group using the 
parameters estimated in the standard treatment group. Martingale residuals, which can be 
thought of as measuring the difference between observed and predicted number of deaths, are 
calculated in the new treatment group and used as a target variable in the stabilized bump 
hunting analysis. Note that residual values close to zero signify good fit of the prognostic 
model to the new treatment data, whereas patients with large residual values have large 
discrepancies between observed and predicted with the prognostic model cumulative hazard.  
In order to identify common factors among patients with large martingale residuals, a 
procedure called bump hunting (Friedman & Fisher, 1999) was applied. Bump hunting creates 
a system of rules involving predictive factors, which identify bumps (i.e. groups) of patients 
with large negative and large positive residuals. Provided that each bump contains patients 
with different survival rates in the placebo and treatment groups (comparison performed with 
the log-rank test or, when needed with an exact version of it), the bump found in the new 
treatment arm would identify patients who are positive or negative responders. The method is 
summarized in the flow diagram of figure 2. For more details, including performance 
evaluation, please, refer to the methodological paper (Kehl & Ulm, 2003).    
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Figure 2: Flow-diagram of the responder identification method. 
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Results 
Data 
The European Myocardial Infarction Amiodarone Trial (EMIAT) was designed to compare 
the drug Amiodarone to placebo with respect to all cause mortality in a double blind setting 
(Julian et al, 1997). It included a total of 1486 survivors of acute myocardial infarction who 
had left ventricular ejection fraction (LVEF) of 40% or less, randomised into two groups of 
743 patients each. There were 103 deaths in the Amiodarone arm and 102 deaths in the 
placebo arm of the study. A total of 1168 patients had Holter recordings available with sinus 
rhythm and at least one ventricular premature beat (VPB), which are necessary for calculation 
of the parameters Onset and Slope – the two components of Heart Rate Turbulence (HRT) 
(Schmidt et al, 1999). This subset of EMIAT had 576 patients in the Amiodarone arm, 86 of 
which died during the two years of follow-up (85% censoring), 592 patients were in the 
placebo group, 82 of which died (86% censoring). Baseline patient characteristics as well as 
categorization schemes can be found in table 1. 
Table 1:  Baseline characteristics of EMIAT for patients with Holter recordings. 
Placebo (n = 592) Treatment (n = 576)  
Variable 
 
Code Name 
 
Dichotomization Mean (SD) Number (%) Mean (SD) Number (%)
Follow-up (days) FOLLOWUP  604.78 (191.94) 605.7 (191.14) 
Censoring DEATH 1 if event 82 (14%)  86 (15%)
Left-ventricular 
ejection fraction LVEF 1 if LVEF ≤ 30 29.92 (7.52) 278 (47%) 30.22 (6.99) 274 (48%)
Age AGE 1 if AGE > 65 60.62 (9.33) 240 (41%) 60.20 (9.67) 219 (38%)
Heart rate at 
initial visit HR 1 if HR > 80 74.69 (14.39) 179 (30%) 74.26 (14.25) 170 (30%)
Heart rate 
variability index HRVI 1 if HRVI ≤ 20 26.08 (10.38) 185 (31%) 26.35 (10.42) 175 (30%)
Onset ONSET 1 if ONSET > 1 0.99 (0.023) 158 (27%) 0.99 (0.026) 148 (26%)
Slope SLOPE 1 if SLOPE ≤ 2.5 6.60 (8.08) 172 (29%) 6.44 (8.39) 189 (33%)
Sex SEX 1 = male 506 (86%)  486 (84%)
More than one 
infarct INFARCT 1 = Yes 157 (27%)  188 (33%)
New York Heart 
Association 
Classification 
NYHA 
2 
3 
1 
251 (42%)
44 (7%)
rest
 264 (46%)
45 (8%)
rest
Diabetes DIABETES 1 = Yes 95 (16%)  98 (17%)
β - blocker  BETABLO 1 = Yes 262 (44%)  255 (44%)
Arrythmia on 
Holter ARRHYTHM 1 = Yes 208 (35%)  211 (37%)
Heart Rate 
Turbulence HRT 
1 if ONSET = 1  
   or SLOPE = 1 
2 if ONSET = 1  
   & SLOPE = 1 
0 if ONSET = 0  
   & SLOPE = 0 
174 (29%)
78 (13%)
rest
 181 (31%)
78 (14%)
rest
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Prognostic Model 
The Cox-PH model summarized in table 2 was developed on the placebo arm of EMIAT 
using stepwise selection methods and was validated internally. The prognostic model we 
found contains the continuous factors left-ventricular ejection fraction (LVEF) and baseline 
heart rate (HR), and the categorical factors “previous infarction” (INFARCT) and Heart Rate 
Turbulence (HRT).  
Table 2: Results of the multivariate Cox model on the placebo group of EMIAT. 
 
 
 
Variable   β p(Wald) Exp(B) 95% CI for Exp(B) 
Lower    Upper 
LVEF -0.035 .013 0.966 0.939     0.993 
HR 0.024 .001 1.024 1.009     1.039 
INFARCT 0.603 .008 1.827 1.171     2.850 
HRT .000   
HRT1 0.599 .030 1.820 1.059     3.128 
HRT2 1.181 .000 3.257 1.818     5.835 
                                                                                                      score statistic = 69.83             
                                                                                                         p(score) = 1.14×10 –13 
 
Predictive Model 
The prognostic model was applied on the Amiodarone arm of EMIAT using the baseline 
hazard function and factor coefficients as estimated in the placebo group. The martingale 
residuals to the prognostic model in the Amiodarone arm were used as a response variable in 
the search for predictive factors. We used a stabilized version of the bump hunting algorithm, 
which used bootstrapping (n = 100) at each border selection step. For details on the original 
and stabilized bump hunting, please refer to Friedman & Fisher (1999) and Kehl & Ulm 
(2003) respectively. The size of the EMIAT data set and most of all its high percent censoring 
do not allow for internal validation, so in order to develop a more stable predictive model, one 
can use pre-defined cut points, i.e. categorize all continuous variables before developing a 
predictive model. For that reason all continuous variables were categorized for use in the 
stabilized bump hunting algorithm (see table 1). The following predictive bump model was 
found on the Amiodarone arm of EMIAT: 
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Negative responders bump  Positive responders bump 
  All not in neg. resp.  bump ∋: 
AGE > 65 
with previous INFARCT 
off BETA-BLOCKER 
 ONSET > 1 
NYHA ≥ 2 
SEX = male 
 
The negative responder bump consists of a box with three borders, which describe patients 
taking Amiodarone who lived shorter than expected by the prognostic model. The positive 
responder bump also consists of a single box with three borders. Patients in that bump lived 
longer than expected. Table 3 represents the growth of the bump model. The rows represent 
model building steps, i.e. change in the model after each "border" addition, starting with the 
entire Amiodarone arm of EMIAT. The p-values of the log-rank test statistic comparing the 
restricted groups in the Amiodarone and placebo arms of EMIAT are also given at each step. 
The "flower" plot of figure 3 represents schematically the structure of the positive and 
negative responder groups. Both bumps define groups of patients who have significantly (at 
the .05 level) different survival estimates under Amiodarone and under placebo (see the 
Kaplan-Meier curves in figure 4). Table 4 gives a cross-tab of censoring and responder group, 
including the number of patients and their mean follow-up time in each subgroup. 56 
Amiodarone patients were placed in the positive responder group by our model. Their actual 
survival time of 632 days (overall mean of 606 days in the Amiodarone arm) was longer than 
that of the corresponding group of 55 placebo patients (506 days), which may be accounted to 
the effect of Amiodarone. From the patients placed in the positive responder group, 2 died in 
the Amiodarone and 16 in the placebo group with verage survival time of 150 and 156 days 
respectively. 57 Amiodarone patients were placed in the negative responder group. Their 
estimated survival time of 494 days was shorter than the average 606 days. 25 of them died 
and their average follow-up time was 277 days. The corresponding group of patients under 
placebo consisted of 58 individuals, 14 of whom died with average survival time of 265 days. 
This, according to our predictive model, could be traced back to the effect of Amiodarone.  
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Table 3: Growth of the bump model in the Amiodarone arm of EMIAT. P-values of the 
log-rank statistic for survival difference between the two treatment arms are 
given at each restriction. Star (*) denotes exact tests. 
 
Bump support: events/patients 
Restricted set 
Amiodarone Placebo 
Log-rank test 
(p-value) 
ALL 86 / 576 82 / 592 .6350 
Negative responders    
AGE > 65 52 / 219 43 / 240 .1766 
AGE > 65 & 
INFARCT = 1 31 / 89 
18 / 80 .0858 
 
AGE > 65 & 
INFARCT = 1 & 
BETABLO = 0 
25 / 57 14 / 58 .0240 
Positive responders    
not negative 
responder & 
ONSET > 1 
19 / 127 34 / 139 .0478 
not negative 
responder & 
ONSET > 1 & 
NYHA ≥ 2 
9 / 81 20 / 73 .0089* 
 
not negative 
responder & 
ONSET > 1 & 
NYHA ≥ 2 & 
SEX = male 
2 / 56 16 / 55 .0002* 
 
 
Table 4: Mean follow-up in cross-tab of censoring and responder groups for the two 
EMIAT arms. 
 
count / mean follow-up censored events total 
+ responders 54 / 650 2 / 150 56 / 632 
− responders 32 / 664 25 / 277 57 / 494 
non-responders 404 / 662 59 / 303 463 / 616 
Amiodarone 
total  490 / 661 86 / 292 576 / 606 
+ responders 39 / 650 16 / 156 55 / 506 
− responders 44 / 681 14 / 265 58 / 580 
non-responders 427 / 662 52 / 268 479 / 619 
Placebo 
total  510 / 663 82 / 246 592 / 605 
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Figure 3: Flower plot of the bump model in the Amiodarone arm of EMIAT. Petals 
represent borders; their intersection – bumps. 
 
Figure 4: Kaplan-Meier survival curve estimates for the a) negative and b) positive 
responder groups of the bump model, compared in the Amiodarone and 
placebo groups of EMIAT. The p-value of the log-rank statistic is .0002* and 
.0240 respectively, where * denotes the result of an exact log-rank test. c) 
shows the rest of the patients.  
 
 
 13
As a rule, among patients with ejection fraction less than 35 (EMIAT population), older 
patients (>65 years) who have had a previous infarction and are not taking beta-blockers seem 
to react particularly negative to Amiodarone, while patients who do not belong to this group, 
i.e. patients who are either taking beta-blockers or have just experienced their first myocardial 
infarction or are younger than 65 years, and in addition are men, have high onset (> 1), and 
pathological NYHA (≥ 2) seem to benefit from Amiodarone treatment. 
 
Discussion 
Applying the method which we have developed, we could identify negative as well as positive 
responders to Amiodaron in the EMIAT study. The comparison between both treatment arms 
leads to significant differences in the survival curves in those subgroups. The negative 
responders to Amiodarone, defined by AGE > 65 years, previous infarction, and no beta-
blockers are at high risk. The 2 years mortality rate after myocardial infarction in the placebo 
subgroup defined by the above parameters was about 25% compared to 47% in the negative 
Amiodarone responder group. The positive responders to Amiodarone identified by: not 
negative responders, onset > 1, NYHA ≥ 2, and male are at low risk. The mortality rate in this 
group under Amiodarone was 4% compared to 30% under placebo. 
In this analysis we distinguish between prognostic and predictive factors. The well established 
prognostic factors such as left-ventricular ejection fraction, heart rate measurements, as well 
as heart rate turbulence showed to be powerful in this data set as well. The factors and 
interactions which may have predictive power in the EMIAT data set were discovered with 
the help of the newly developed responder identification method. Those factor interactions 
need further investigation in a setting similar to that of the EMIAT study.  
A major weakness of the bump hunting model in the responder identification method is the 
fact that up to now it has no goodness of fit criteria. Sometimes it is possible to perform 
internal or external validation, but in most cases, just as in EMIAT, the size of the data does 
not allow splitting and no suitable data sets are available for external validation. Stabilized 
bump hunting, however, performs very well even on data with few events (see simulation 
study in Kehl & Ulm).  Its power for negative responders is 99% and for positive responders 
90%. That means, that out of 100 models, the procedure recognizes correctly at least 90.  In 
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our opinion, the power of the procedure compensates somewhat the lack of goodness of fit 
criteria.  
The interpretability of the resulting models is another positive feature, which makes the 
responder identification method attractive in the area of clinical trials.   
The method can also be applied to studies in which there is an overall difference in survival 
between the two treatment groups. For further details, please refer to the methodological 
paper (Kehl & Ulm, 2003). 
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